SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Applied Digital Corp. is a technology company, which engages in the provision of development and operation of data centers which provide computing power. It operates through the Data Center Hosting Business and HPC Hosting Business segments. The Data Center Hosting Business segment provides energized infrastructure services to crypto mining customers. The HPC Hosting Business segment focuses on the designing, constructing, and operating data centers tailored to support high power density applications like HPC and AI. The company was founded by Wesley Carl Cummins and Jason Zhang in May 2001 and is headquartered in Dallas, TX.

Applied Digital Corporation

APLD is trending following a positive earnings report and increased guidance, sparking excitement about its potential in the AI data center space. The community is actively discussing the possibility of a short squeeze and future hyperscaler deals, while some caution against overvaluation and potential algorithmic selling. Despite differing opinions, bullish sentiment appears to be dominating the conversation surrounding APLD.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon's stock is trending as traders eye a potential breakout, fueled by optimism around AI and cloud growth. Community members are actively discussing short-term price movements and potential options plays, with some anticipating a run towards higher price targets. Despite some bearish sentiment and concerns about lagging performance, many bulls believe AMZN is undervalued and poised to catch up with its mega-cap peers.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath ($PATH) is trending as community members discuss its potential for a short squeeze, fueled by high short interest and significant call option volume at the $20 strike. Some investors believe the stock is undervalued compared to peers and are drawing comparisons to Palantir's early growth, citing UiPath's shift towards AI and partnerships with major tech companies as catalysts for future gains. Others are focused on technical analysis, highlighting breakout potential and resistance levels.

SEALSQ Corp. is a holding company, which engages in the security of microcontrollers. It operates through the following geographical segments: North America, Europe, Middle East, Africa, Asia Pacific, and Latin America. It focuses on authentication process, digital certification, and covering individual patents of semiconductors. The company was founded on April 1, 2022 and is headquartered in Cointrin, Switzerland.

SEALSQ Corp

SEALSQ Corp ($LAES) is trending due to its partnership to develop quantum-resistant chips for U.S. defense, fueling speculation of government contracts and a potential short squeeze. The community is comparing it to other quantum stocks like $IONQ and $RGTI, with many believing it's undervalued and poised for significant growth. Discussions also highlight upcoming catalysts, including a satellite launch and the release of a new chip.

TeraWulf, Inc. owns and operates fully integrated environmentally clean bitcoin mining facilities in the United States. TeraWulf will generate domestically produced bitcoin powered by nuclear, hydro and solar energy. The company was founded by Paul Prager and Nazar Khan on February 8, 2021 and is headquartered in Easton, MD.

TeraWulf Inc

TeraWulf (WULF) is trending as the community discusses its potential to catch up with sector peers like APLD and IREN, particularly due to its increasing focus on AI and high-performance computing data centers. Discussions revolve around a possible short squeeze, fueled by high short interest and a large amount of call options, with some speculating on price targets and the impact of upcoming earnings and potential catalysts like the Cayuga site approval. Some investors point to the backing of Google as a catalyst for growth.

GSR III Acquisition Corp engages in the merger, share exchange, asset acquisition, share purchase or reorganization with one or more businesses. The company was founded on May 10, 2023 and is headquartered in Austin, Texas.

GSR III Acquisition Corp. - Ordinary Shares- Class A

GSR III Acquisition Corp. Ordinary Shares

GSRT is trending due to the upcoming merger with Terra Innovatum, with the ticker symbol slated to change to NKLR, a catchy name in the nuclear sector; the merger vote is scheduled for early October. The community is excited about the ticker change and is comparing the company to sector peers, anticipating a significant rise in valuation post-merger, although some caution about potential volatility.

One and one Green Technologies. Inc - Ordinary Shares - Class A

One and one Green Technologies ($YDDL) is trending following its IPO, with significant after-hours volatility and considerable interest due to its low float. Community members are actively discussing potential overnight holds, possible price targets, and the company's business model as a waste management and scrap metal recycling company in the Philippines. Many are also comparing it to other recent IPOs with similar price action.

Siyata Mobile, Inc. engages in the provision of cellular communications systems for enterprise customers. It specializes in connected vehicle products for professional fleets, marketed under the Uniden Cellular and Siyata brands. The firm operates through the following geographical segments: Europe, the Middle East and Africa; Unites States; Canada; and Australia and New Zealand. The company was founded by Marc Seelenfreund on October 15, 1986 and is headquartered in Montreal, Canada.

Core AI Holdings Inc.

Core AI Holdings, Inc.

Core AI Holdings ($CHAI) is trending as investors express frustration and confusion following its NASDAQ debut after a reverse merger, citing a lack of communication and disappointing price action; the community is actively discussing concerns around financials, the merger's purpose, and potential short attacks, while also questioning the company's strategy. Some are hopeful for a turnaround pending news and brokerages resolving trading issues, while others voice deep skepticism and regret, comparing it to past disappointments.

The Hershey Co. engages in the manufacture and marketing of chocolate, sweets, mints and confectionery products. The firm operates through the following segments: North America Confectionery, North America Salty Snacks and International. The North America Confectionery segment is responsible for the traditional chocolate and non-chocolate confectionery market position of the company, as well as its grocery and snacks market positions, in the United States and Canada. The North America Salty Snacks segment is responsible for the salty snack products in the United States. The International segment includes the combination of all other operating segments, including those geographic regions where the company operates outside of North America. Its brands include Hershey's, Reese's, and Kisses. The company was founded by Milton S. Hershey in 1894 and is headquartered in Hershey, PA.

Hershey Company

Hershey is trending amid speculation of a potential acquisition by Mondelez, driving significant price movement. Community discussions revolve around the likelihood of the deal given Hershey's trust structure and previous rejections, as well as the potential impact of cocoa prices and consumer demand on a combined entity. Analysts are weighing in on the potential valuation and strategic fit within the broader food and beverage sector.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP) is experiencing heightened activity as traders debate its potential amid observations of low volume and historical underperformance relative to other cryptocurrencies. Community members are closely watching governance proposals and treasury management, while also speculating on potential catalysts like staking and updates from the Compound Foundation. Discussions also involve technical analysis, with some anticipating a breakout due to its low float and others expressing frustration with its price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Merus&nbsp;NV’s stock climbed to a record high on Monday after Genmab said it would acquire the company in an $8 billion all-cash transaction, despite a broad wave of analyst downgrades.<a href="https://stocktwits.com/symbol/MRUS">Shares of Merus</a> jumped 36% to close at $93.70 on Monday, before edging up 0.1%, in after-hours trading.Needham analyst Ami Fadia downgraded Merus to ‘Hold’ from ‘Buy’ without a price target after the company entered into the agreement. Citi downgraded the stock to ‘Neutral’ from ‘Buy’ and cut its price target to $97 from $101, saying the possibility of a competing bid is very low.Wells Fargo analyst Eva Fortea Verdejo lowered her rating to ‘Equal Weight’ from ‘Overweight’ and raised the price target to $97 from $95. Canaccord downgraded Merus to ‘Hold’ from ‘Buy’ with a price target of $97, while William Blair cut its rating to ‘Market Perform’ from ‘Outperform’.Truist moved Merus to ‘Hold’ from ‘Buy’ and raised the price target to $97 from $88, saying the deal terms are “favorable, all things considered.”LifeSci Capital analyst Charles Zhu downgraded Merus to ‘Market Perform’ from ‘Outperform’ with a price target of $97. Guggenheim analyst Michael Schmidt downgraded the stock to ‘Neutral’ from ‘Buy’ and cut the target to $97 from $109.H.C. Wainwright downgraded Merus to ‘Neutral’ from ‘Buy’ and reduced its price target to $97 from $135, saying Merus’ full value is priced into the deal.The transaction, unanimously approved by both companies’ boards, gives Genmab full ownership of petosemtamab, Merus’ late-stage antibody therapy for head and neck cancer, which has received two Breakthrough Therapy Designations from the U.S. Food and Drug Administration.On Stocktwits, retail sentiment for Merus was ‘extremely bullish’ amid a 3,800% surge in 24-hour message volume.Some users congratulated Merus shareholders on the buyout, saying the acquisition marked a rewarding moment for long-term investors who held through difficult periods.<stembedurl>https://stocktwits.com/BiotechBonesaw/message/630422083</stembedurl><stembedurl>https://stocktwits.com/Following_the_trend/message/630325826</stembedurl>Another user noted that the deal underscored the potential for other biotech firms to be acquired at higher valuations, citing that Merus was acquired by Genmab for $8 billion, despite its focus on the relatively smaller head and neck cancer market.<stembedurl>https://stocktwits.com/Power2k/message/630394868</stembedurl><a href="https://stocktwits.com/symbol/MRUS">Merus’ stock</a> has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Merus logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Merus Stock Soars To All-Time High As Genmab Announces $8B Takeover — Analysts Turn Cautious, Retail Crowd Cheers The Deal

The $8 billion all-cash deal gives Genmab full ownership of Merus’ late-stage antibody therapy petosemtamab, which has received two FDA Breakthrough Therapy Designations for head and neck cancer.

Equity

Retail chatter around Merus spiked late on Sunday after a report said Denmark’s Genmab is reportedly in advanced talks to acquire the Dutch biotech, which is developing a potential treatment for head and neck cancer.<a href="https://stocktwits.com/symbol/MRUS">Merus’ U.S.-listed stock</a> closed at $68.89 on Friday, up 1.2%, and surged over 19% to $82.03 in overnight trading.Merus has reportedly received multiple takeover offers from large pharmaceutical companies in recent weeks and could announce a deal within days, although there is no certainty that the talks will result in a transaction, Bloomberg&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-09-28/genmab-is-said-in-talks-to-buy-cancer-drugmaker-merus?srnd=homepage-americas&amp;sref=8QBk7toa">reported</a>, citing people familiar with the matter.If finalized, the deal would be Genmab’s largest acquisition to date, Bloomberg reported. Genmab has a market capitalization of about 118 billion kroner ($18.5 billion), while Merus is valued at around $5.2 billion on the Nasdaq.Merus’ shares have risen sharply since May, when the company said its experimental drug petosemtamab was more effective than the current standard of care in shrinking tumors in head-and-neck cancer patients when combined with Keytruda. Bloomberg Intelligence has forecast that the drug could become a blockbuster therapy and exceed $1 billion in sales by 2030.Merus is also testing petosemtamab in advanced colon cancer, a larger and more lucrative potential market. Its smaller rival, Bicara Therapeutics, is developing a treatment for the same condition but remains further behind in development.On Stocktwits, retail sentiment for Merus was ‘bullish’ amid ‘high’ message volume, placing the stock among the top ten trending equities on the platform. Meanwhile, Genmab drew ‘extremely bearish’ sentiment amid ‘high’ message volume.One user congratulated the company on the reported development, while another user asked about the potential buyout price, reflecting curiosity about the rumored deal’s details.<stembedurl>https://stocktwits.com/CrispDry/message/630278149</stembedurl><stembedurl>https://stocktwits.com/Fugazi_/message/630280727</stembedurl>Merus’ U.S.-listed stock has risen 63.8% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Merus Buyout Rumor Gets Retail Traders Buzzing — Genmab Said To Be Leading The Race

Merus’ cancer drug petosemtamab, developed for head and neck tumors, has shown stronger results than the current standard of care and is projected to top $1 billion in annual sales by 2030.

Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma, teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease, and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.

Genmab - ADR

Will JP Morgan Chase ($JPM) beat quarterly earnings?  
 
*Powered by Polymarket

Stocktwits

JPMorgan Chase & Co

) beat quarterly earnings?  
 
*Powered by Polymarket

GMXAY
GENMAB A/S/S ADR

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest GMXAY News

GMXAYGENMAB A/S/S ADR